Tango Therapeutics
Develops MTAP-selective PRMT5 inhibitors for genetically defined cancers.
$23.49
After-hours close+0.13 (+0.56%)
At close$23.36(−7.59%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.34 | — | — |
| Aug 2026 | −$0.32 | −$0.37 | −16.6% |
| Aug 2026 | −$0.32 | −$0.37 | −16.6% |
| May 2026 | −$0.32 | −$0.32 | 0.0% |
| Mar 2026 | −$0.31 | −$0.29 | +6.5% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| Jul 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | −$0.34 | — | — | $3.3M | — | — |
| Aug 11, 2026 | −$0.32 | −$0.37 | −16.6% | $1.6M | $0 | −100.0% |
| Aug 10, 2026 | −$0.32 | −$0.37 | −16.6% | $1.6M | — | — |
| May 13, 2026 | −$0.32 | −$0.32 | 0.0% | $578.1K | — | — |
| Mar 5, 2026 | −$0.31 | −$0.29 | +6.5% | $500.4K | — | — |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | ||||||
| Nov 4, 2025 | ||||||
| Aug 5, 2025 | ||||||
| May 12, 2025 | ||||||
| Feb 27, 2025 | ||||||
| Nov 6, 2024 | ||||||
| Aug 7, 2024 | ||||||
| May 8, 2024 | ||||||
| Mar 18, 2024 | ||||||
| Nov 8, 2023 | ||||||
| Aug 7, 2023 | ||||||
| May 9, 2023 | ||||||
| Mar 27, 2023 | ||||||
| Nov 10, 2022 | ||||||
| Aug 10, 2022 | ||||||
| May 11, 2022 | ||||||
| Mar 28, 2022 | ||||||
| Nov 9, 2021 | ||||||
| Aug 6, 2021 | ||||||
| Jul 17, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Nov 13, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||